# Gene Editing T-Cells to Fight CD7 Blood Cancers

> This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.

- **Patent:** US 12564648
- **Original title:** Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
- **Owner:** Washington University in St. Louis
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, gene_editing, oncology

## What it does

This patent outlines a method for treating CD7 positive hematologic cancers, which are types of blood cancer, in humans. It involves administering specially modified human T cells. These T cells are engineered to express a Chimeric Antigen Receptor (CAR) that specifically binds to a protein called CD7, which is found on the cancer cells (Claim 1a). Crucially, these T cells have two genetic modifications: a first 'indel' (a small insertion or deletion) in their own CD7 gene, making them 'CD7 deficient' (Claim 1b), and a second indel in their T cell Receptor Alpha Chain (TRAC) gene, making them 'TRAC deficient' (Claim 1c). The CD7 modification prevents the CAR-T cells from attacking each other (a problem called fratricide, Claim 7), while the TRAC modification helps prevent the modified cells from attacking the patient's healthy tissues (called alloreactivity or Graft-versus-Host Disease, Claim 10). For example, this method could be used to treat T-cell acute lymphoblastic leukemia (T-ALL) by infusing these specially prepared T cells into a patient (Claim 11, 12).

## What it does NOT cover

- Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
- Does not cover CAR-T cells that lack a specific genetic modification (indel) in their own CD7 gene.
- Does not cover CAR-T cells that lack a specific genetic modification (indel) in their T cell Receptor Alpha Chain (TRAC) gene.
- Does not cover CAR-T cells where the genetic modifications are not 'indels' (e.g., gene insertions or point mutations).
- Does not cover methods for treating cancers that are not CD7 positive hematologic cancers.
- Does not cover CAR-T cells modified to prevent fratricide or alloreactivity through non-genetic means or different genetic targets.

## The clever bit

The truly clever part is the dual genetic modification of the CAR-T cells themselves. By making the T-cells deficient in CD7, they become 'fratricide-resistant,' meaning they won't attack each other even while targeting CD7 on cancer cells. Simultaneously, disabling the T cell Receptor Alpha Chain (TRAC) prevents the engineered cells from causing harmful immune reactions against the patient's healthy body, a significant safety improvement.

## Real-world examples

1. CAR-T cell therapies for blood cancers
2. Gene-edited cell therapies
3. Treatments for T-cell acute lymphoblastic leukemia (T-ALL)
4. Treatments for T-cell lymphoblastic lymphoma (T-LBL)
5. Treatments for T-cell non-Hodgkin's Lymphoma (T-NHL)

## Why it matters

Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood cancers, specifically those that express CD7.

## Frequently asked questions

### What does Gene Editing T-Cells to Fight CD7 Blood Cancers cover?

This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.

### Who owns patent US 12564648?

Washington University in St. Louis owns this patent, granted in 2026.

### When does this patent expire?

This patent is expected to expire on April 24, 2045, when the invention enters the public domain.

### What problem does this patent solve?

Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood…

### What does this patent NOT cover?

Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).

**Full plain-English explainer:** https://patentbrief.org/patent/us/12564648/gene-editing-of-car-t-cells-for-the-treatment-of-t-cell-malignancies-with-chimer

**Original patent:** https://patents.google.com/patent/US12564648

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [How Genetically Modified T-Cells Attack Cancer](https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer) — This patent describes how human T cells are genetically engineered to express a special receptor (CAR) that specifically targets and kills cancer cells, particularly those with the CD19 marker, offering a new way to treat cancer.
- [How Genetically Modified T-Cells Fight CD19 Cancers](https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer) — This patent describes how to create and use genetically modified human T cells that target and kill cancer cells expressing the CD19 protein, offering a new way to treat blood cancers.
- [Making Better CAR-T Cells to Fight Lymphoma](https://patentbrief.org/patent/us/12630603/chimeric-antigen-receptor-t-cell-therapy-12630603) — This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.
- [Treating a Specific Lymphoma with Modified T Cells](https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy) — This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.
- [Targeting Cancer with CAR T Cells Using a Chemical Tag](https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy) — This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that recognize a chemical tag, which is attached to a small drug molecule, along with a separate folate compound.
